Tonix Pharmaceuticals Holding Corp. TNXP
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Tonix Pharmaceuticals Holding Corp. (TNXP) is a healthcare company listed in the US with a market value of about $58M. In the twelve months to September 30, 2026 it had revenue of $43M and net income of -$181M, a net margin of -420.4%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -54%.
About Tonix Pharmaceuticals Holding
Tonix Pharmaceuticals Holding is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 10 years in our data. Its share count rose by 313177% over three years (dilution for shareholders). It spends 339% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $43M | $13M | $10M | $8M | — | — | — | — | — | — | — |
| Net income | -$181M | -$124M | -$130M | -$117M | -$110M | -$92M | -$50M | -$29M | -$26M | -$21M | -$39M |
| Free cash flow | -$170M | -$103M | -$61M | -$110M | -$146M | -$111M | -$57M | -$27M | -$24M | -$19M | -$37M |
| EPS (diluted) | $-12.41 | $-14.57 | $-176.60 | $-14720.25 | $-43022.91 | $-106551.70 | $-7234.99 | $-254277.08 | $-3418204.78 | $-416867.08 | $-2027113.47 |
| Net margin | -420.4% | -946.2% | -1288.2% | -1501.8% | — | — | — | — | — | — | — |
| ROIC | — | -40.3% | -72.6% | -79.6% | -42.6% | -33.2% | -44.9% | -233.0% | -87.9% | -68.3% | -121.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $34.00, 1030% above the current price; targets range from $18.00 to $64.00; the consensus rating is “Strong buy”; expected EPS is $-10.91 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Tonix Pharmaceuticals Holding pay a dividend?
Not currently.
Is Tonix Pharmaceuticals Holding a good stock to buy?
We do not give buy or sell advice. Tonix Pharmaceuticals Holding scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.